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Introduction: In 1996, the International Association for the Study
of Lung Cancer (IASLC) launched a worldwide TNM staging
project to inform the next edition (seventh) of the TNM lung cancer
staging system. In this article, we describe the methods and valida-
tion approaches used and discuss the internal and external validity of
the recommended changes.
Methods: The International Staging Committee agreed on a number
of general principles that guided the decision-making process. In-
ternal validity was addressed by visually assessing the consistency
of Kaplan-Meier curves across database types, geographic regions
and addressing external validity, by assessing the similarity of
curves generated using the population-based Surveillance Epidemi-
ology and End Results cancer registry data to those generated using
the project database. Cox proportional hazards regression was used
to calculate hazard ratios between the proposed stage groupings with
adjustment for cell type, sex, age, and region.
Results: Calls for data by the International Staging Committee
resulted in the creation of an international database containing
information on more than 100,000 cases. The present work is based
on analyses of the 67,725 cases of non-small cell lung cancer.
Validation checks were robust, demonstrating that the suggested
staging changes are stable within the data sources used and exter-
nally. For example, suggested changes based on tumor size were
well supported, with statistically significant hazard ratios ranging
from 1.14 to 1.51 between adjacent pairs in the Surveillance Epi-
demiology and End Results data.
Conclusions: Lung cancer stage definitions have never been sub-
jected to such an intense validation process. We do accept, however,
that this work is limited in ways that can only be addressed by a
prospective database, which we intend to develop. In the meantime,
we think that this new system will greatly improve the usefulness of
TNM lung staging across all of its purposes.
Key Words: TNM classification, Non-small cell lung cancer, Stag-
ing validity, International database.
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In 1996, the International Association for the Study of LungCancer (IASLC) launched a worldwide TNM staging
project to create international databases that would be used to
continue the excellent efforts of Dr. Cliff Mountain, who
pioneered this approach to lung cancer staging in 1973.1–3
Successive iterations of TNM staging for lung cancer
have addressed shortcomings identified by the oncology com-
munity. Similarly, the IASLC recognized that it is important
that further revisions continue to be made to ensure that the
international staging system for lung cancer remains fit for its
purpose. The work of the International Staging Committee
(ISC) that oversaw the conduct of this study will inform the
seventh edition of the international staging system for lung
cancer.
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The ISC identified the following issues that needed to
be rectified:
1. There was a lack of validation for individual T, N, and
M descriptors in previous iterations.
2. The relatively small database on which previous revi-
sions have been based made it unlikely that the indi-
vidual descriptors had been adequately assessed.
3. This previously used database was recruited from a
limited geographic area and was predominately com-
posed of surgical cases.
4. Criticisms in the literature needed to be addressed and
reconciled.
This article, written by the Validation and Methodology
Subcommittee of the ISC, describes the methods and valida-
tion approach used in this retrospective phase of the ongoing
IASLC staging initiative and discusses the internal and ex-
ternal validity of the T, N, and M category changes and the
stage groupings that are being recommended by the ISC.
METHODS
The IASLC is the only global organization dedicated to
the study of lung cancer, with members involved in all aspects of
lung cancer diagnosis, imaging, management, and research.
Therefore, the IASLC thought that it was ideally placed to
organize a large, international database of lung cancer cases
collected from diverse geographic areas and managed by all
modalities of care. The ISC that oversaw the conduct of this
study was established in 1998. Further details regarding the
project development have been described elsewhere.3 At a
meeting held in London in 2001, representatives from 23 insti-
tutions in 12 countries presented data from their individual
databases representing in excess of 80,000 cases. Calls for data
eventually increased this number to more than 100,000.
As the project progressed, the ISC created subcommit-
tees to manage the various elements of the project3:
1. T Descriptors Subcommittee
2. N Descriptors Subcommittee
3. M Descriptors Subcommittee
4. Small-Cell Lung Cancer
5. Nodal Chart Subcommittee
6. Prognostic Factors Subcommittee
7. Validation and Methodology Subcommittee
Cancer Research and Biostatistics, a nonprofit organi-
zation based in Seattle, WA, with extensive experience in the
conduct and analysis of multicenter studies in North America,
is managing and analyzing the project database. Cancer
Research and Biostatistics has been responsible for collect-
ing, translating, and compiling the data, creating a data
dictionary, and providing the subcommittees with analyses
that have informed our recommendations.
Guiding Principles
The ISC agreed on a number of general principles that
guided the decision-making process throughout this project:
1. Recommendations should be based on cTNM (clinical
TNM) and pTNM (pathologic TNM) to ensure rele-
vancy to all who are diagnosed with lung cancer.
2. Changes should not compromise the use of data from
the previous staging system whenever possible.
3. Evidence from external sources should be included in
our deliberations.
4. Unproven descriptors should be “flagged” for a later
prospective phase.
In a subsequent breakout session, the Validation and Meth-
odology Subcommittee recommended the following addi-
tional principles:
5. Design a system that is identical for both pathologic and
clinical staging.
6. If boundaries between categories are to be changed,
there should be overwhelming evidence to support such
changes. This criterion is in recognition of TNM Gen-
eral Rule 6.4
7. Stage grouping boundaries are not constrained by con-
dition 2 listed above.
8. Surgical cases where there was residual disease at the
resection margins, being either microscopic (R1) or
macroscopic (R2), should be included in the analyses,
provided there were no significant changes to the patho-
logic staging conclusions
9. The prognostic ability of the revised staging system
should be verified by a multivariate analysis that con-
siders other prognostic factors, i.e., histology, age, sex.
Study Population
Collaborating institutions were recruited through an-
nouncements in the journal Lung Cancer, by presentations
at the IASLC World Conferences and at other conferences
and workshops. Institutions known to have data were
contacted directly by members of the ISC. Data were
accepted from all parts of the globe for all modalities of
care, including best supportive care. The time frame was
defined as all patients treated between the beginning of
1990 and the end of 2000. Cases were screened for
adequate follow-up, histology, and baseline TNM staging.
Methods used to compile the database are described in
detail elsewhere.3
The total number of patients submitted to Cancer Re-
search and Biostatistics was 100,869. Of these, 81,015 passed
the initial screening requirements of having a new diagnosis
rather than a diagnosis of recurrent disease, of either small-
cell lung cancer (SCLC) or non-small cell lung cancer
(NSCLC), adequate follow-up for survival calculations, and a
complete set of either cTNM or pTNM at baseline. Results of
the initial screening requirements are summarized in Table 1,
updating our previous report.3
Of the 81,015 patients passing the initial screen, 36%
were treated with surgery only, 11% with radiotherapy alone,
21% with chemotherapy alone, 9% with best supportive care
or no treatment, and the remaining patients were managed
with combined treatment modalities. The distributions by
stage and geographic region for included cases of SCLC and
NSCLC are given in Figure 1.
A small number of cases had been submitted from
series or registries and also from clinical trial groups, which
may have caused duplication of cases. Where identifiers
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permitted or in regions where specific clinical trial participa-
tion was known, double entries were excluded. However, it
was not possible to quantify accurately all such cases.
The study population that passed the initial screening
criteria contained 67,725 cases of NSCLC and 13,290 cases
of SCLC. The two groups were analyzed separately, and as
the focus of this article is the NSCLC cases, the SCLC cases
have been excluded from further discussion.
The NSCLC study population included 53,640 clini-
cally staged cases and 33,933 pathologically staged cases,
with 20,006 cases both clinically and pathologically staged.
The groups who contributed these NSCLC cases to the
project are summarized in Table 2, classified according to the
definitions listed.
1. Clinical trial: participants in studies designed to inves-
tigate alternate treatments
2. Population-based registry: all individuals diagnosed
with lung cancer in a defined region, including those
diagnosed at death
3. Institutional registry: all individuals diagnosed with
lung cancer and admitted to a particular institution
4. Consortium: same as institutional registry but spanning
multiple institutions
5. Series: all individuals diagnosed with lung cancer and
treated by a particular doctor or service
6. Surgical series: all individuals diagnosed with lung
cancer and treated by a particular surgeon or surgical
unit
The geographic source of the 67,725 NSCLC patients by
continent was as follows: 40,059 from Europe, 12,178 from
North America, 10,216 from Asia, and 5,272 from Australia.
Ninety-five percent were followed until death or at least 2 years;
and 88%, until death or 5 years. Median follow-up for the
17,754 patients alive at last contact was 5.3 years.
Endpoints and Statistical Methods
Survival was measured from the date of entry (date of
diagnosis for registries, date of registration for protocols) for
clinically staged data and the date of surgery for pathologi-
cally staged data to the date of death or last contact and was
calculated by the Kaplan-Meier method.5 For the external
validation analyses, Cox proportional hazards regression was
used to calculate hazard ratios (HRs) between adjacent
groups and to assess the prognostic value of the proposed
stage groupings in both the test set and the external valida-
tion. In that instance, given the large number of cases avail-
able, adjustment for cell type, sex, age, and region was
conducted. All analyses were conducted using the SAS Sys-
tem for Windows Version 9.0.
Validation Methodology
Because the data collected were from diverse sources and
are not, strictly speaking, population based, we were concerned
that conclusions reached may be biased. The Validation and
Methodology Subcommittee was formed to address this concern
by making recommendations about a validation approach and
interpreting the validation analyses. Specifically, the mandate of
this committee was to ensure that the recommendations for
change were internally and externally valid and that the project
would meet Union Internationale Contre le Cancer methodolog-
ical expectations.
The internal validation approach was to compare results
of interest among types of databases (consortium/surgical
series versus clinical trials versus series/registries) and among
geographic regions (North America versus Australasia versus
Europe). If the direction and magnitude of effects were
relatively consistent within these subgroups, that would be
considered evidence validating the results. Survival curves
were visually compared using all cases with the relevant
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FIGURE 1. Stage distribution by continent non-small cell
lung cancer (A) and small-cell lung cancer (B).
TABLE 1. Initial Screening of Submitted Cases
Total cases submitted 100,869
Passed initial screen for SCLC and NSCLC analyses 81,015
Excluded 19,854
Carcinoid 546
Other tumors (sarcoma, other) 569
Other reasons
Outside 1990–2000 time frame 5443
Incomplete survival data 1505
Unknown histology or occult 2468
Incomplete stage information 7720
Recurrent case (or unknown status) 1536
Duplicate cases removed 67
SCLC, small-cell lung cancer; NSCLC, non-small cell lung cancer.
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information and also comparing pTNM curves separately
from cTNM curves. We did not conduct statistical tests
during the validation stage as the numbers often varied
widely between data sources, thereby compromising the use-
fulness of statistical comparisons. For internal validation of
the T component analysis by size, a training set of two thirds
of the cases was used for testing and validated in the other
one third of cases. Similarly, internal validation of proposed
stage groupings was conducted by holding out a validation set
of one third of the cases.
For external validation, cases of NSCLC diagnosed
from 1998 to the end of 2000 from the Surveillance,
Epidemiology, and End Results Program (SEER) database
were chosen.6 This time frame offered the most detailed
extent of disease data. Given the nature of these data, we
assigned stage using pTNM when available and cTNM
otherwise, that is, using best stage. Hazard ratios and
significance levels were calculated for pairwise compari-
sons of adjacent categories.
In general, our conclusions discounted deviant re-
sults when they were based on unstable curves that were
the result of small numbers. Our overarching goal was to
ensure that no large, deviant subset drove our final recom-
mendations and that whenever it was possible (i.e., the
data were available), our results were reflected in our
population-based external data set.
RESULTS
Internal and External Validity of Suggested
Changes to the T Categories
The following are observations of the Validation and
Methodology Subcommittee, in support of the recommenda-
tions of the T Subcommittee. Table 3 contains a summary of
the Kaplan-Meier survival results and Figures 2 and 3 show
the results of our external validation analyses. A supplemen-
tal appendix of the Kaplan-Meier survival curves for the
internal validity comparisons is available on this journal’s
Web site. Changes referred to below are described in the
paper on the ISC T-category recommendations.7
Change 1: Subclassify T1 as T1a and T1b by Size
On balance, this finding is both internally and exter-
nally valid. Referring to Table 3, we found that the pT
finding was clearly driven by the Australasian data, which
made up 62% (2322 of 3579) of cases, with a median
survival of 124 months for T1a and 103 months for T1b.
The European cT data also showed distinct differences in
survival with median survival 64 and 46 months, respec-
tively. When we examined this split by database type, the
series/registry subset (19% of pN0 cases used) was not as
distinct as the consortia/surgical subset with differences in
median survival of 6% and 16%, respectively. Clinical
staging was available on only 3283 subjects, whereas
pathologic stage was available for 9007. Referring to the
clinically staged results, the North American clinical trial
and registries/series subsets, which made up 23% of the
whole, were not able to distinguish between these groups.
As shown in Figure 2, the SEER external validation in the
N0 population supports the split with a 4% difference at 5
years and an HR of 1.27 (p  0.04) and in the surgical
subset of the SEER, whose staging would have been
pathologic, the HR was 1.16 (p  0.02) (data not
shown).
TABLE 2. Screened NSCLC Cases by Type of Contributing Group
Clinical Trial Groups Registries Consortia Surgical Series
MacCallum 183 Amsterdam 8897 Japan 6931 China 1732
MRC 1659 Flemish 3590 IFCT 2539 Korea 832
IFCT 920 Rotterdam 1133 GCCB-S 2894 Sydney 1572
ELCWP 1385 Institutional Registry Series Prince Charles 773
IALT 1867 Heidelberg 4455 Taiwan 721 St. Vincent’s 17
SLCG 438 Surgical Registry QRI 2452 Gdansk 1231
EORTC 1123 Norway 2112 Western 275 Torino 1137
CALGB 1830 Faculty Hospital, Plzen 1486 Grenoble 677
NCCTG 1111 Leuven 770 Ankara 543
ECOG 1737 Jules-Bordet 547 Belgrade 344
SWOG 1859 MDACC-RT 840 Warsaw 213
RTOG 1768 Johns Hopkins University 851 Perugia 99
NCIC 550 MSKCC 880
MDACC-TCVS 489
Prince Margaret 191
Wayne State University 72
MRC, Medical Research Council; IFCT, Intergroupe Francophone deCancerologie Thoracique; GCCB-S, Bronchogenic Carcinoma Co-operative Group of the Spanish Society
of Pneumology and Thoracic Surgery; ELCWP, European Lung Cancer Working Party; IALT, International Adjuvant Lung Cancer Trial; SLCG, Spanish Lung Cancer Group;
EORTC, European Organization for Research and Treatment of Cancer; CALGB, Cancer and Leukemia Group B; HSP, NCCTG, North Central Cancer Treatment Group; ECOG,
Eastern Cooperative Oncology Group; SWOG, Southwest Oncology Group; RTOG, Radiation Therapy Oncology Group; NCIC, National Cancer Institute of Canada; QRI,
Queensland Radium Institute; MDACC-RT, M.D. Anderson Cancer Center–Radiation Therapy; MDACC-TCVS, M.D. Anderson Cancer Center–Thoracic and Cardiovascular
Surgery; MSKCC, Memorial Sloan-Kettering Cancer Center.
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Change 2: Subclassify T2 as T2a and T2b by Size
This finding was consistent across regions with the
exception of the Australasian clinical results, where the
numbers were small (n  145) and the North American
pathologic results, where the curves do not split until 3 years.
Both the pathologically staged results and the consortia/
surgical clinically staged results are consistent and stable, but
the number of clinically staged T2b cases was small in the
clinical trial and registry/series sources. Overall, for those
instances in which the curves were stable, the difference in
median survival ranged from 10% to 27% (Table 3). The
SEER external validation in the N0 population strongly
supports the split both overall (Figure 2, 14% difference at 5
years, HR  1.51, p  0.0001) and in the surgical subset
(15% difference at 5 years, HR  1.45, p  0.0001, data not
shown).
Change 3: Reclassify T2 Tumors Larger than 7 cm
as T3
Referring to Table 3, median survival differences be-
tween those subjects with previously staged T2 tumors larger
than 7 cm and those with T3 disease were generally small,
ranging from 2% to a 14% difference. Where the differ-
ences were greatest, the numbers were small: 21 clinically
staged and 46 pathologically staged T2 7 cm cases in the
North American subset, and 17 clinically staged T2 7 cm
cases in the clinical trial subset. The population-based SEER
data indicate some similarity between the T2b group and the
T2 7 cm group (HR  1.15, p  0.09), but the T2 7 cm
and T3 curves are statistically significantly different with an
HR of 1.18 (p  0.05) observed, and this finding is more
stable when all SEER cases (including N) are considered
(HR  1.27, p  0.0001, data not shown).
Change 4: Reclassify T4 Tumors by Additional
Nodules in the Primary Lobe as T3
Referring to Table 3, with the exception of the North
American subset, which was small, cases with additional
nodules in the primary lobe experienced better survival than
other sixth edition T4 cases, with differences in median
survival of 7% in the Australasian group and 5% in the
European group. Median survival differences were similar by
database type: 6% in the consortia/surgical group and 9% in
the registry/series group. We were not able to look at this
issue using cTNM because this data element was only avail-
able from the surgical data. Referring to the SEER data
presented in Figure 3, we can see an extremely large differ-
ence in survival between those with T4 disease due to
additional nodules in the same lobe compared with the rest
(HR  1.9, p  0.0001). When we restricted to those treated
with surgery in the U.S. SEER data, the additional nodule
group’s survival was better than those even with sixth edition
T3 disease (5-year survival rate, 40% and 27%, respectively,
data not shown). Note that the SEER Program T3 group
excluded those with disease in the adjacent rib.
Change 5: Reclassify M1 by Additional Nodules in
the Ipsilateral Lung (different lobe) as T4
This finding was driven by the consortia/surgical patho-
logic data source (n  168/180) that was also almost all from
the Australasian region (n  136/180) in which median
survival between the additional nodules group was 4% and
6% higher than the “Other T4” patient group. The European
pathologic data support the change (n  43) in that the curve
for these patients is quite similar to the “Other T4” group
(data not shown), although median survival is 5% lower.
Referring to Figure 3, the SEER data indicate that the 11-
month median survival of this group falls above the other T4
cases (9 months) with a HR of 0.86 (p  0.0002).
Validation of the Decision to Make No
Changes to the N Categories
The following are observations of the Validation and
Methodology Subcommittee in support of the recommenda-
tion of the N Subcommittee to retain the current N category
definitions. Table 4 contains a summary of the Kaplan-Meier
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survival results comparing the existing TNM N categories by
region and database type, and Figure 4 shows the results of
our external validation analyses of those categories. A sup-
plemental appendix of the Kaplan-Meier survival curves for
the internal validity comparisons is available on this journal’s
Web site. Further details regarding this recommendation are
provided in the paper on the ISC N-category recommendations.8
The prognostic value of the TNM sixth edition N
categories were validated internally by comparing the sur-
vival curves of cM0 cases across geographic regions and
database types in the IASLC database. All subsets of the
IASLC data set generated N category survival curves that
were prognostically distinct. However, the degree of spread
among the curves varied, likely reflecting variability in case
mix within N categories among the geographic regions and
data types. Referring to Table 4, the cN0 to cN3 median
survival difference ranged from 21 months in Europe to 59
months in Australasia. The difference in median survival
between cN0 and cN3 was smaller in the clinical trials data
(13 months) compared with registries (19 months) and con-
sortia/series (50 months). The position of the curves also
varied. For example, the median survival of cN0 patients was
29 months in Europe, 43 months in North America, and 70
months in Asia.
External validation was assessed using the SEER data
presented in Figure 4. Each curve is prognostically distinct,
although the difference between the N2 and N3 curves is
smaller than what we observed in the IASLC data set overall8
(median survival difference of 2 months in SEER and 5
months in IASLC). The paper presenting the ISC N-category
recommendations proposes areas for further investigation
when more detailed data become available.8
Internal and External Validity of Suggested
Changes to the M Categories
The following are observations of the Validation and
Methodology Subcommittee in support of the recommenda-
tions of the M Subcommittee. Table 5 contains a summary of
the Kaplan-Meier survival results comparing the existing
TNM N categories by region and database type and Figure 5
shows the results of our external validation analyses of those
categories. A supplemental appendix of the Kaplan-Meier
survival curves for the internal validity comparisons is avail-
able on this journal’s Web site. Changes referred to below are
described in the paper on the ISC M-category recommenda-
tions.9
Change 1: Reclassify Pleural Dissemination
(malignant pleural or pericardial effusions, pleural
nodules) from T4 to M1
The distinction between this group and the other T4
patients was driven by the European and North American
data in the clinically staged analyses. In these regions, the
median survival difference between those with pleural dis-
semination and those with any T4 M0 disease was 5% and
6%, respectively (Table 5), and the curves are divergent
throughout follow-up (see online supplemental appendix).
The finding was consistent in two of the three data types, and
the curves diverge after the first year in the registry/series
group (see online supplemental appendix). Referring to Fig-
ure 5, the SEER data support the external validity of this
finding with 4-month median survival for those patients with
malignant pleural effusions compared with 10 months for all
other T4s.
TABLE 4. Median Overall Survival in Months among Subgroups Compared in the Conduct of
Internal Validity Checks for Investigation of TNM Sixth Edition N Categories, cN0–cN3, cM0 Only
Region Database Type
NA
(n  6942)
A/Au
(n  10,220)
Eur
(n  21,100)
C/S
(n  14,190)
R/S
(n  16,445)
CTs
(n  7626)
cN0 43 70 29 62 27 23
cN1 24 32 18 38 17 18
cN2 17 20 12 22 11 14
cN3 12 11 8 12 8 10
NA, North America; A/Au, Asia and Australia; Eur, Europe; C/S, Consortia and Surgical Series; R/S, Registries and Series; CTs, clinical
trials.
SEER N for M0 patients (1998+)
0%
20%
40%
60%
80%
100%
0 1 2 3 4 5
Survival, Years
N0
N1
N2
N3
Deaths / N
6178 / 11800
1650 / 2412
6324 / 7292
873 / 962
Median
in Months
37
21
9
7
<.00011.26vs N2:7%31%N3
<.00011.89vs N1:7%41%N2
<.00011.52vs N0:24%63%N1
37%74%N0
PHRComparison5 Yrs1 Yr
FIGURE 4. Overall survival by TNM sixth edition N cate-
gory in Surveillance, Epidemiology, and End Results Program
(SEER) and results of pairwise comparisons.
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Change 2: Subclassify M1 into M1a and M1b
Referring to Table 5, those patients with metastatic
disease attributable to distant metastases had a worse median
survival (4–7 months) than those with pleural dissemination
(7–10 months) or those with disease spread to the contralat-
eral lung (9–11 months). The ordering of these findings was
consistent across regions and database types (see online
supplemental appendix). Referring to Figure 5, the SEER
data show less separation between patients with pleural dis-
semination versus patients with distant metastases; however,
the ordering matches that of the IASLC data that are the basis
of this recommendation.9
Internal and External Validity of the Stage
Grouping System
The following are observations of the Validation and
Methodology Subcommittee, in support of the recommenda-
tions of the IASLC International Staging Committee. Figures
6 and 7 and Tables 6 through 9 present the results of the
validation analyses of these proposed stage groupings.
Changes referred to below are described in the paper on the
ISC TNM stage grouping recommendations.10 Note that these
changes are proposed partly to improve prognostication but
also to ensure that the groups are clinically sensible with
regard to treatment considerations. This aspect of the deci-
sion-making process is described in the companion paper.10
The internal validity of the proposed TNM grouping
scheme was assessed via the subset of data reserved as the
validation data set. Tables 6 through 9 summarize the results
of Cox proportional hazards regression applied to the valida-
tion set data, modeling the proposed grouping scheme with
adjustment for cell type, sex, age, and region. A parallel
analysis of the TNM, sixth edition (TNM 6) applied to the
same data set is included for reference. The proposed group-
0%
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60%
80%
100%
0 1 2 3 4 5
Survival, Years
IA
IB
IIA
IIB
IIIA
IIIB
IV
Deaths / N
135 / 281
229 / 424
79 / 146
525 / 755
818 / 1072
225 / 257
889 / 928
Median
in Months
58
42
46
19
14
10
6
A
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0 1 2 3 4 5
Survival, Years
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IIA
IIB
IIIA
IIIB
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326 / 1281
421 / 1044
435 / 862
468 / 760
930 / 1288
94 / 103
66 / 86
Median
in Months
NR
NR
50
30
20
13
21
NR:  Median not reached at 60 months
B
FIGURE 6. Overall survival by proposed TNM stage group-
ings, validation data set, clinical stage (A), and pathologic
stage (B).
TABLE 5. Median Overall Survival in Months among Subgroups Compared in the Conduct of
Internal Validity Checks for Proposed M Category Changes
Region Database Type
NA
(n  2212)
A/Au
(n  317)
Eur
(n  3063)
C/S
(n  908)
R/S
(n  1973)
CTs
(n  2711)
T4 M0 any N 16 10 12 21 7 16
Pleural dissemination 10 8 7 7 7 10
Contralateral lung nodules 11 9 10 — 10 10
M1 distant 7 5 5 6 4 7
NA, North America; A/Au, Asia and Australia; Eur, Europe; C/S, Consortia and Surgical Series; R/S, Registries and Series; CTs, clinical
trials.
<0.0011.14M1 Distant vs Pleural Dissem.
<.00011.52vs Contra Lung:1%15%M1 Dist Metastasis
<0.0010.75vs Pleural Dissem:4%31%M1 Contra Lung
<.00012.81vs T4:2%21%T4 Pleural Dissem.
7%40%T4 Other 
PHRComparison5 Yrs1 Yr
SEER Selected T4/M1 (1998+)
0%
20%
40%
60%
80%
100%
0 1 2 3 4 5
Survival, Years
1. T4 Other
2. Pleural Dissem.
3. M1 Contra Lung
4. M1 Dist Metastasis
Deaths / N
3922 / 4492
4612 / 4841
1904 / 2064
15509 / 15996
Median
in Months
10
4
6
3
FIGURE 5. Overall survival of T4 and M1 minus same-side
nodules in Surveillance, Epidemiology, and End Results Pro-
gram (SEER) and results of pairwise comparisons.
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ings were prognostically distinct using clinical stage for
pairwise comparisons from stage IIA on, but not for compar-
isons between the early staged groups (Tables 6 and 7). Of
note, the same failure occurred for TNM 6 and may be due to
a peculiarity of the smaller subset of early stage cases in the
clinically staged validation data set. The validation exercise
did reproduce the improvement achieved by the proposed
subgroupings in the separation of stages IIA and IIB for
clinical stage.
For pathologic stage (Tables 8 and 9), application of the
proposed subgroupings to the validation data set achieved the
same general results as when applied to the training set and to
all available cases as reported previously.10 Improvements in
the R2 value for the proposed grouping scheme are small but
persistent in the validation set analyses, both for clinical and
pathologic staging. Survival curves for the proposed TNM
subgrouping generated on the validation set data are shown
for clinical and pathologic stages in Figure 6.
External validation was assessed via SEER best stage
as shown in Figure 7. Both TNM 6 and the newly proposed
system perform as expected but with some deficiencies.
0%
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80%
100%
0 1 2 3 4 5
Survival, Years
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IIA
IIB
IIIA
IIIB
IV
Deaths / N
1612 / 4276
2140 / 4371
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1082 / 1665
2684 / 3377
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4
B
FIGURE 7. Overall survival by best stage in SEER: TNM
sixth edition (A) and IASLC proposed (B).
TABLE 6. Cox Proportional Hazards Regression Models for
TNM 6 and Proposed Clinical Stage Groupings (IASLC),
Validation Data Set: Clinical Stage (TNM 6 and IASLC
Proposed) as Indicator Variables
HR for Comparison p
Comparisons TNM 6 IASLC TNM 6 IASLC
IB vs. IA 1.14 1.07 0.1886 0.5330
IIA vs. IB 1.12 1.03 0.7965 0.8178
IIB vs. IIA 1.46 1.72 0.3977 0.0001
IIIA vs. IIB 1.36 1.34 0.0001 0.0001
IIIB vs. IIIA 1.42 1.45 0.0001 0.0001
IV vs. IIIB 1.87 1.83 0.0001 .0001
R2 26.35 27.15
Adjusted for cell type, sex, age, and region; n 3863 (2999 events). TNM 6, TNM
sixth edition; HR, hazard ratio; IASLC, International Association for the Study of Lung
Cancer.
TABLE 7. Cox Proportional Hazards Regression Models for
TNM 6 and Proposed Clinical Stage Groupings (IASLC),
Validation Data Set: Clinical Stage (TNM 6 and IASLC
Proposed) as an Ordered Variable
HR p
Variable TNM 6 IASLC TNM 6 IASLC
Stage 1.40 1.43 0.0001 0.0001
Adjusted for cell type, sex, age, and region; n 3863 (2999 events). TNM 6, TNM
sixth edition; HR, hazard ratio; IASLC, International Association for the Study of Lung
Cancer.
TABLE 8. Cox Proportional Hazards Regression Models for
TNM 6 and Proposed Pathological Stage Groupings (IASLC),
Validation Data Set: Pathologic Stage (TNM 6 and IASLC
Proposed) as Indicator Variables
HR for Comparison p
Comparisons TNM 6 IASLC TNM 6 IASLC
IB vs. IA 1.75 1.57 0.0001 0.0001
IIA vs. IB 1.17 1.33 0.1498 0.0001
IIB vs. IIA 1.30 1.38 0.0170 0.0001
IIIA vs. IIB 1.54 1.47 0.0001 0.0001
IIIB vs. IIIA 1.28 2.00 0.0004 0.0001
IV vs. IIIB 0.79 0.65 0.1269 0.0063
R2 29.32 30.76
TNM 6, TNM sixth edition; HR, hazard ratio; IASLC, International Association for
the Study of Lung Cancer. Adjusted for cell type, sex, age, and region; n  5424 (3016
events).
TABLE 9. Cox Proportional Hazards Regression Models for
TNM 6 and Proposed Pathologic Stage Groupings (IASLC),
Validation Data Set: Pathologic Stage (TNM 6 and IASLC
Proposed) as an Ordered Variable
HR p
Variable TNM 6 IASLC TNM 6 IASLC
Stage 1.35 1.41 0.0001 0.0001
TNM 6, TNM sixth edition; HR, hazard ratio; IASLC, International Association for
the Study of Lung Cancer. Adjusted for cell type, sex, age, and region; n  5424 (3016
events).
Groome et al. Journal of Thoracic Oncology • Volume 2, Number 8, August 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer702
For TNM 6, the separation between stages IB and IIA is
weak out to 2 years. For the proposed system, stages IIA
and IIB nearly converge at 5 years. For either system,
stages IIIB and IV are ordered appropriately and separate
well. The proposed system results in a more even distri-
bution of cases among the stage groupings in this popula-
tion-based registry, primarily due to a larger proportion of
cases assigned to stage IIA.
DISCUSSION
The currently accepted staging system for NSCLC was
adopted in 1997 by the American Joint Committee on Cancer
and the Union Internationale Contre le Cancer,4 as a response
to the need for more specific patient groupings. The intent of
this staging system was to provide a consistent and reproduc-
ible classification for describing the extent of disease. At the
same time, it was intended to provide a prognostic tool to
guide clinicians in their treatment choices, as well as being a
common language for lung cancer clinicians and researchers
throughout the world.
Numerous articles have suggested deficiencies in the
current international staging system, and none of these were
addressed by TNM 6.4 For instance, concerns have been
expressed in regard to a number of descriptors; most notably,
the possibility that size criteria other than the 3-cm cutoff that
separates T1 and T2 tumors may be significant.11–14 Two
recent articles using a Spanish database suggest that this
cutoff be replaced with cuts at 2, 4, and 7 cm and that tumors
7 cm be considered T3.12,13 Other studies support the 3-cm
cutoff and add an additional cut at 5 cm.13,14 This example
underscores the controversies that have been discussed in the
literature and it also supports the recommended changes to T
stage by size made by the ISC.7 In addition, the appropriate-
ness of the designation given to additional pulmonary nodules
in certain locations has been questioned,15,16 and there have
been suggestions for change of the stage groupings.17,18
However, the validity of all the studies, individually and collec-
tively, is limited by one or more shortcomings, which cause
them to fall below the standards set by the Union Internationale
Contre le Cancer Process for Change Subcommittee.19
The purpose of the ISC over the past 5 years has been
to address these deficiencies using the power of numbers
accrued in our international database, together with sophisti-
cated statistical methods and expert advice from members of
the global oncology community. This has been a remarkable
initiative, but we have some concerns about the limitations of
the data. First, several significant geographic areas were not
represented. These include the old USSR, South America,
Africa, and China. Second, because this was an opportunistic
use of existing data sets, we had to make use of data that had
been collected for other purposes. So some data fields were
missing from each of the data sets. Because we needed extent
of disease information beyond TNM stage, the availability of
these data in particular varied across the various data sets. As
much as possible, the ISC considered the degree of coverage
of each variable in its deliberations. Third, the precision of
clinical staging, and even pathologic staging, may be subject
to variability. This variability will almost always linked to
local practices, which determine what level of evidence is
required to assign a stage grouping. Although it is not
possible to measure the impact of inconsistent staging prac-
tices, we do want to point out that such variation is actually
reflective of what goes on in practice. That said, some
prognostic differences may have been masked by staging
inconsistencies in our data. In this context, we think that both
random and systematic errors would have attenuated our
ability to see prognostic differences and that our examination
of the data by type and region has helped to ensure that no
errors have occurred in the other direction, that is, declaring
prognostic differences when they do not exist. This study is a
classic example of the trade-off that often occurs between
control over data quality and applicability of research find-
ings to the widest group. Last, given the large number of data
sources that we used and their wide geographic coverage, we
expect that treatment practices and treatment quality would
have varied. It was not possible for us to control for the
prognostic impact of treatment for two reasons: (1) control-
ling for treatment in a multivariate analysis would have
interfered with our ability to see extent of disease effects due
to the problem of confounding by indication and (2) we had
no information about treatment quality per se. However, our
data did include patients treated with the full spectrum of
treatment options, including no treatment and best supportive
care. If there is a treatment-related bias in our findings, it is
likely in the direction of reducing our ability to see prognostic
differences.
We used the SEER registries’ data as our external
validation source. These registries are the reference standard
by which other registries in the world are measured, and they
contain detailed extent of disease information that allowed us
to assess key aspects of TNM staging. Because SEER is
population based, the entire spectrum of lung cancer presen-
tation is represented. We are not aware of any published
findings on the accuracy of the SEER extent of disease data.
However, referring to our Figures 4 and 7A, which report the
SEER data split by the current TNM N categories and the
current TNM stage groups respectively, we find that the wide
separation of these curves is evidence of the prognostic
validity of the SEER extent of disease assignment.
In the next phase of its work, the ISC is planning to
widen its geographic coverage and move into primary data
collection that will include purposeful retrospective data
capture up to 2007 and prospective data capture starting in
2008. With more control over data collection and better
geographic coverage, we will be able to further inform lung
cancer staging. Specifically, the goal of this next phase will
be to make proposals for consideration in the eighth edition of
the TNM classification.
CONCLUSION
We have, with successive revisions of the TNM staging
system, become comfortable with established treatment algo-
rithms that have become linked to designated stages of
disease. Some of our recommendations will force us all to
readdress these links and perhaps change some of these
algorithms. However, we should remember that previous
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revisions have been informed by a smaller database that was
never subjected to the intense validation process that we have
used. In this respect, our recommendations are more robust
than any previous submission. We accept that it is still limited
in ways that can only be addressed by the next phase of our
work, but, in the meantime, we also believe that this new
system for lung staging will greatly improve the usefulness of
TNM lung staging across all its purposes.
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